世界*實驗材料供應(yīng)商 Dianova 正式授權(quán)上海起發(fā)為其中國代理， Dianova 在一直是行業(yè)的*,一直為廣大科研客戶提供zui為的產(chǎn)品和服務(wù),上海起發(fā)一直秉承為中國科研客戶帶來的產(chǎn)品，的服務(wù)，簽約 Dianova 就是為了給廣大科研客戶帶來更加完善的產(chǎn)品和服務(wù),您的滿意將是我們zui大的收獲

 Dianova 中國代理, Dianova 上海代理， Dianova 北京代理，Dianova 廣東代理， Dianova 江蘇代理Dianova 湖北代理,Dianova 天津,Dianova 黑龍江代理,Dianova 內(nèi)蒙古代理,Dianova 吉林代理,Dianova 福建代理, Dianova 江蘇代理, Dianova 浙江代理, Dianova 四川代理,

Dianova公司為德國的病理免疫組化產(chǎn)品供應(yīng)商，具備的抗體制備工藝及嚴(yán)格的質(zhì)控系統(tǒng)，產(chǎn)品在上享有良好的聲譽。

克隆號為H09的IDH1（isocitrate dehydrogenase 1, 異檸檬酸鹽脫氫酶1）鼠單克隆抗體為Dianova公司近期推出的產(chǎn)品之一，此抗體可特異性的檢測腦組織腫瘤中IDH1基因的R132H點突變。IDH1基因的第132密碼子的雜合突變是II 和III級神經(jīng)膠質(zhì)瘤（根據(jù)WHO的腫瘤學(xué)分類）的頻發(fā)事件。在大約70％的星形膠質(zhì)細(xì)胞瘤和少突神經(jīng)膠質(zhì)細(xì)胞瘤可發(fā)現(xiàn)IDH1基因的R132H點突變。

IDH1基因R132H突變在部分腦腫瘤中的頻發(fā)現(xiàn)象使克隆號為H09的IDH1抗體可高靈敏性和高特異性的用于此類腫瘤的鑒別診斷中：如從原發(fā)性膠質(zhì)母細(xì)胞瘤中區(qū)分出間變性星形細(xì)胞瘤、從毛細(xì)胞型星形細(xì)胞瘤或室管膜（細(xì)胞）瘤中區(qū)分出彌漫性星形細(xì)胞瘤（WHO分類II級），也可以用于具有IDH1突變的腫瘤細(xì)胞浸潤前沿的與反應(yīng)性神經(jīng)膠質(zhì)增多癥的區(qū)分。因此，由于其高靈敏性和高特異性，此抗體在腦部腫瘤的分類分級中以及在檢測單一或少量浸潤腫瘤細(xì)胞時是非常有用的。

DIA-W09 – Anti-IDH1 (Hu) aus Ratte (Klon: W09) – unkonj. – 500 µl

Art.-Nr.                        DIA-W09

Spezifität                      IDH1

Spezies-Reaktivität             Human

Wirtsspezies                     Ratte

Isotyp                           IgG2a

Klon                             W09

Klonalität (Mono-/Polyklonal)     monoklonal

Anwendung                        Western Blot

                                 Immunhistochemie (IHC)
                                 Immunhistochemie (Paraffingewebe)

Konjugation                      unkonjugiert

Format                           ProteinA/G-gereinigt (aus Kulturüberstand)

                                 Lyophilisat

Produktlinie / Thema             Neurobiologie

                                 Tumormarker/-biologie
                                 Immunhistochemie

Zweckbestimmung                  nur für Forschungszwecke

Suchcode                          DIA W09

                                  FFPE
                                  Paraffin

Hersler / Marke                dianova

Reactivity

Isocitrate dehydrogenase (IDH) is an important enzyme in the citric acid cycle and catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate and CO2 while converting NAD+ to NADH. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximay 70% of astrocytomas and oligodendroglial tumors. Mouse antibody clone H09 (product number #DIA-H09)reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. Therefore this antibody is highly useful for tumor classification. Rat antibody clone W09 detects both wild type (wt) and point mutated IDH1 in glioblastoma (anti-pan-IDH1) and serves as control for the IDH1 point mutation specific mouse antibody clone H09. Moreover, Tan et al. (Mol Cell Proteomics, 2011) have identified IDH1 as a potential diagnostic and prognostic biomarker for Non-small-cell Lung Cancer (NSCLC). These findings suggest that anti-IDH1wt antibody could be used as a histochemical biomarker for prognosis prediction of NSCLC.

Immunohistochemistry of human IDH1 R132H and human IDH1 wild-type in formalin-fixed paraffinembedded glioblastoma.

A: No reaction of IDH1 R132H mutation specific antibody clone H09 with glioblastoma (200x)
B: Strong reaction of anti-pan-IDH1 specific antibody clone W09 with the same glioblastoma (200x)
C: No reaction of IDH1 R132H mutation specific antibody clone H09 with glioblastoma (400x)
D: Strong reaction of anti-pan-IDH1 specific antibody clone W09 with the same glioblastoma (400x)

A

B

C

D

(pictures courtesy of Prof. Dr. med. Andreas von Deimling, Department of Neuropathology, University Heidelberg / Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany)

References

• Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20(1): 245-254, 2010

Related References

• Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, Li N, Qiu B, Gao Y, Li B, Tan X, Zhou F, Wang Z, Ding D, Wang J, Sun J,Hang J, Feng X, Shi S, He F, He J.. Identification of IDH1 as a Potential Diagnostic and Prognostic Biomarker for Non small-cell Lung Cancer by Proteomic Analysis. Mol Cell Proteomics 2011 Nov 7. (Epub ahead of print)

部分產(chǎn)品信息如下：

我們公司zui大優(yōu)勢是強(qiáng)大的采購，

1：基本什么都能進(jìn)口，血清，抗體，耗材，還有部分限制進(jìn)口的，

2：貨品全，現(xiàn)經(jīng)營過700多個品牌，基本所有生物試劑耗材都可以進(jìn)口，特別是冷偏的產(chǎn)品那就更有優(yōu)勢，

3：提供加急服務(wù)，一般1-2周到貨，超過時限加急費全免

4：價格公道，絕大部分價格有優(yōu)勢，當(dāng)然不能保證100%產(chǎn)品都是,因為意味著沒有服務(wù).

5：良好的信譽，大部分客戶我們提供貨到付款服務(wù)，客戶包括清華，北大 交大 復(fù)旦，中山等100多所大學(xué)，ROCHE，阿斯利康，國藥 ，fisher等500多家公司

6：我們還是Santa,Advanced Biotechnologies Inc, Dianova,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. Dako,Inc, GePromegaridege,Dianova  Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Dianova , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國外公司授權(quán)代理。
7：我們還是invitrogen,qiagen,Midland BioProducts Corporationam,sigma;neb,roche,merck, rnd,BD, GE,pierce,BioLegend等知名*批發(fā)，歡迎合作。